Ocular Therapeutix

Ocular Therapeutix, Inc. is a biopharmaceutical company committed to redefining the retina experience across drug development, treatment, and outcomes.

[Ocular Therapeutix @OCUTX]

Today, we announced positive results from the landmark SOL-1 Phase 3 superiority trial in wet AMD, an important step forward as we aim to reduce the treatment burden, with the data presentation taking place at Macula Society this month.

Learn more: https://t.co/yU7m9QxmmG

[Ocular Therapeutix @OCUTX]

We’re thrilled to be joined by Arshad Khanani, MD, Darius Moshfeghi, MD, and Lejla Vajzovic, MD, FASRS for our Investor Day, where they’ll share perspectives on the current retinal disease landscape.

Learn more about what we will discuss on June 17: https://t.co/tsvVt8M6dv

[Ocular Therapeutix @OCUTX]

What could sustained disease control mean for future management of wet AMD? Retina leaders share how maintaining stable vision and retinal anatomy over time could help address the challenges associated with current treatment approaches.

Explore more: https://t.co/K1BZlnoNNq

[Ocular Therapeutix @OCUTX]

At @RWCRetina, retina leaders discussed durability's role in the management of wet age-related macular degeneration, focusing on how longer-acting treatments may reduce treatment burden, support disease control, and improve outcomes.

Explore more: https://t.co/vRvXxi7jeg

[Ocular Therapeutix @OCUTX]

Retina leaders at @RWCRetina discussed the future of wet AMD care, exploring the importance of clinical trial design that evaluates durability, meaningful endpoints, and the potential to improve long-term outcomes for patients.

Explore more: https://t.co/VzbocNmbpT

[Ocular Therapeutix @OCUTX]

At the Royal College of Ophthalmologists Congress, Adnan Tufail, MBBS, MD, Darius M. Moshfeghi, MD, and Dilsher Dhoot, MD spotlighted new analyses related to our landmark SOL-1 Phase 3 clinical trial.

Learn more: https://t.co/KmucCkfUom

#RetinaRedefined

[Ocular Therapeutix @OCUTX]

Our Executive Chairman, President, and CEO Pravin Dugel, MD will join @Stifel’s Ophthalmology Conference to discuss the future of retinal disease treatment and insights from our landmark SOL-1 Phase 3 superiority clinical trial in wet AMD.

Learn more: https://t.co/pfM8OXHVxa

[Ocular Therapeutix @OCUTX]

Investor Day is almost here, and we’re excited to connect on June 17 at 2:00 PM ET in New York City. We’ll share updates on our strategy, momentum across the business, and commitment to advancing the future of retina care through innovation.

Learn more: https://t.co/aD18gVDmKl

[Ocular Therapeutix @OCUTX]

At @RetinaWCongress, our team was proud to share data from our landmark SOL-1 Phase 3 superiority clinical trial in wet age-related macular degeneration with the global retina community.

Learn more about our mission to redefine the retina experience: https://t.co/8jYdtHRoXZ

[Ocular Therapeutix @OCUTX]

This content discusses an investigational drug, OTX‑TKI (AXPAXLI™), currently in development. Its safety and efficacy have not been established, and it is not approved for marketing by the FDA or any other health authority.

[Ocular Therapeutix @OCUTX]

Patricio Schlottmann, MD presented on the landmark SOL‑1 Phase 3 clinical trial in wet AMD at @ARVOinfo. He highlighted how clinical trial design may help inform the future of durability and sustained disease control in retinal care.​

Learn more: https://t.co/4ws8ykOa7D

[Ocular Therapeutix @OCUTX]

At @ARVOinfo, Andrew Moshfeghi, MD shared findings from a real-world analysis of anti‑VEGF treatment utilization and vision outcomes in wet AMD, focusing on how treatment burden may contribute to suboptimal long‑term visual outcomes. Learn more: https://t.co/WbHuoJVn5Y

[Ocular Therapeutix @OCUTX]

Ocular’s Chief Development Officer Peter Kaiser, MD will present at @RetinaWCongress Unplugged. He plans to discuss our novel approach across clinical trial development as we aim to improve long-term outcomes.

Visit us at booth 2 and learn more at https://t.co/3Nj8zZ06n3.

[Ocular Therapeutix @OCUTX]

At @BankofAmerica’s Global Healthcare Conference, our Executive Chairman, President, and CEO Pravin Dugel, MD shared updates on our clinical programs in wet AMD and diabetic retinopathy. ​

Learn more about our mission to redefine the retina experience: https://t.co/L5qgJilMaX

[Ocular Therapeutix @OCUTX]

Christina Weng, MD, MBA, FASRS presented IRIS registry findings that showcased how early vision improvements with anti‑VEGF therapy may decline over time for patients with wet AMD at @ARVOinfo. ​

Learn more: https://t.co/TqLPiyn5Nq

[Ocular Therapeutix @OCUTX]

We’re excited for @RetinaWCongress and to share data from our SOL-1 Phase 3 trial in wet age-related macular degeneration.​ We look forward to sharing how we’re working to redefine the retina experience.

Visit us at booth 2 and learn more: https://t.co/Vpu91lylw9

[Ocular Therapeutix @OCUTX]

The @BankofAmerica Global Healthcare Conference kicks off tomorrow, where our Executive Chair, President, and CEO Pravin Dugel, will discuss our clinical trial programs and key insights around our SOL-1 Phase 3 trial data.

Learn more: https://t.co/nWHdv3WO3l

[Ocular Therapeutix @OCUTX]

Our team enjoyed engaging with the retina community and continuing conversations around our landmark SOL-1 Phase 3 trial in wet age-related macular degeneration at @ARVOinfo, reflecting our commitment to advancing retinal disease care.

Learn more: https://t.co/5g2VxVUJTP

[Ocular Therapeutix @OCUTX]

Today, we shared our Q1 2026 earnings, highlighting updates across our clinical trials in retinal disease. This progress highlights our focus on advancing potential long-acting treatment options for retinal disease.

Learn more: https://t.co/d8mT37Np0T

#RetinaRedefined

[Ocular Therapeutix @OCUTX]

It was great connecting with those who attended @Eyecelerator on how thoughtful clinical trial design and innovation in retinal research can shape the patient experience.

Learn more: https://t.co/JKABqtIRih

#Eyecelerator #RetinaRedefined

[Ocular Therapeutix @OCUTX]

We’re looking forward to connecting with the retina community at the Cole Eye Institute Retina Summit.​

Visit our booth and learn more about how we’re working to transform the future of retinal disease care: https://t.co/vzb93pz29W​

#RetinaRedefined